Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer
• * Recurrent or progressive disease
• Received at least 1 prior platinum-based chemotherapy regimen containing carboplatin, cisplatin, or another organoplatinum compound for primary disease
• * May include high-dose therapy, consolidation, or extended therapy after surgical or non-surgical assessment
• No brain metastases or leptomeningeal involvement
• PATIENT CHARACTERISTICS:
• Age:
• Not specified
• Performance status:
• Karnofsky 70-100%
• Life expectancy:
• Not specified
• Hematopoietic:
• Absolute neutrophil count at least 1,000/mm\^3
• Platelet count at least 100,000/mm\^3
• Hemoglobin at least 8.0 g/dL
• Hepatic:
• AST and ALT no greater than 2.5 times upper limit of normal
• Bilirubin no greater than 1.8 mg/dL
• Renal:
• Creatinine no greater than 1.5 mg/dL
• Cardiovascular:
• LVEF greater than 50% by radionuclide ventriculogram or two-dimensional echocardiogram
• No peripheral vascular disease requiring surgical management
• No prior myocardial infarction
• No congestive heart failure
• No orthostatic hypotension
• No acute ischemia or significant conduction abnormality (bifascicular block, defined as left anterior hemiblock with right bundle branch block, second or third degree AV blocks) as evidenced by electrocardiogram
• No prior cerebrovascular event
• Other:
• No peripheral neuropathy grade 2 or greater
• No other serious medical or psychiatric illness
• Not pregnant
• Negative pregnancy test
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• Not specified
• Chemotherapy:
• See Disease Characteristics
• No more than 2 prior regimens for recurrent disease, including 1 non-platinum containing regimen
• At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas and mitomycin) and recovered
• Endocrine therapy:
• At least 1 week since prior hormonal therapy directed at primary tumor
• Concurrent hormone replacement therapy allowed
• Radiotherapy:
• Not specified
• Surgery:
• See Disease Characteristics
• At least 2 weeks since prior major surgery